Skip to main content

Table 1 Baseline characteristics of patients

From: Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin

Protective strategyDexrazoxaneContinuous infusionCrossover
Total Number81110
Age25–6924–7123–66
Sex (M/F)3/57/43/7